|
|
|
CORT Dividend History & Description — Corcept Therapeutics Inc
Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Co. has marketed Korlym (mifepristone) in the U.S. for the treatment of patients with Cushing's syndrome. Co.'s primary compounds have entered the clinic as potential treatments for serious disorders, including Cushing's syndrome, solid tumors (such as ovarian cancer, castration-resistant prostate cancer and adrenocortical cancer with cortisol excess), antipsychotic induced weight gain and non-alcoholic steatohepatitis. When considering the Corcept Therapeutics Inc stock dividend history, we have taken known splits into account, such that the CORT dividend history is presented on a split-adjusted ("apples to apples") basis. Corcept Therapeutics Inc dividend history is presented both in graphical/chart form, and as a CORT dividend history data table along the right-hand column.
|
CORT Stock Dividend HistoryThe CORT dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable CORT historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the CORT dividend history record. Also see the CORT stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Strong Buy (4.00 out of 4)
100th percentile
|
PARTNER NEWS:Wed, Apr 17, 10:00 AM, Zacks
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Wed, Apr 17, 5:26 AM, Zacks
New Strong Buy Stocks for April 17th BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank 1 (Strong Buy) List on April 17, 2023.
|
|